Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company, is receiving advisory services and conditional funding from the National Research Council Industrial Research Assistance Program (NRC IRAP) to support the development of Orion’s lead compound, OB-002, a promising treatment for SARS-CoV-2 infection associated acute respiratory distress syndrome (ARDS).   OB-002 is the first of a new class of drugs, called Chemokine Analogs, being developed by Orion Biotechnology leveraging ...